{"result": "(\"entity\"<|>AMIODARONE<|>ORGANIZATION<|>Amiodarone is a widely used drug for various cardiac conditions, primarily as an antiarrhythmic, known for its high iodine content which can affect thyroid function.)\n##\n(\"entity\"<|>THYROID DISEASE<|>EVENT<|>Thyroid disease refers to various conditions affecting the thyroid gland, including hypothyroidism and hyperthyroidism, which can be influenced by medications like amiodarone.)\n##\n(\"entity\"<|>HYPOTHYROIDISM<|>EVENT<|>Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormones, which can occur as a side effect of amiodarone treatment.)\n##\n(\"entity\"<|>HYPERTIROIDISM<|>EVENT<|>Hyperthyroidism is a condition characterized by excessive production of thyroid hormones, which can also be a side effect of amiodarone.)\n##\n(\"entity\"<|>TIROCYTE<|>ORGANIZATION<|>Tirocytes are the cells of the thyroid gland that can be affected by drugs like amiodarone, leading to cytotoxic effects.)\n##\n(\"entity\"<|>AMIODARONE TREATMENT<|>EVENT<|>Amiodarone treatment refers to the administration of amiodarone for managing cardiac arrhythmias, which can have implications for thyroid function.)\n##\n(\"entity\"<|>THYROID RECEPTORS<|>ORGANIZATION<|>Thyroid receptors are proteins that bind thyroid hormones and can be downregulated by amiodarone, affecting hormone action.)\n##\n(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association provides guidelines for the diagnosis and management of thyroid disease, including during pregnancy.)\n##\n(\"entity\"<|>PREGNANCY<|>EVENT<|>Pregnancy is a condition that can complicate the management of thyroid disease and the use of medications like amiodarone.)\n##\n(\"entity\"<|>REFERENCES<|>ORGANIZATION<|>References are various studies and guidelines that provide evidence and recommendations regarding thyroid disease and treatments.)\n##\n(\"relationship\"<|>AMIODARONE<|>THYROID DISEASE<|>Amiodarone can induce thyroid disease, including both hypothyroidism and hyperthyroidism, as a side effect of its use<|>8)\n##\n(\"relationship\"<|>AMIODARONE<|>HYPOTHYROIDISM<|>Amiodarone treatment can lead to the development of hypothyroidism in patients<|>7)\n##\n(\"relationship\"<|>AMIODARONE<|>HYPERTIROIDISM<|>Amiodarone treatment can lead to the development of hyperthyroidism in patients<|>7)\n##\n(\"relationship\"<|>AMIODARONE<|>TIROCYTE<|>Amiodarone has cytotoxic effects on tirocytes, leading to potential thyroid dysfunction<|>9)\n##\n(\"relationship\"<|>AMIODARONE<|>THYROID RECEPTORS<|>Amiodarone can downregulate thyroid receptors, affecting the action of thyroid hormones<|>6)\n##\n(\"relationship\"<|>AMIODARONE TREATMENT<|>THYROID DISEASE<|>The treatment with amiodarone is associated with the risk of developing thyroid disease<|>8)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>THYROID DISEASE<|>The American Thyroid Association provides guidelines for the management of thyroid disease<|>5)\n##\n(\"relationship\"<|>PREGNANCY<|>THYROID DISEASE<|>Pregnancy can complicate the management of thyroid disease and the use of medications like amiodarone<|>4)\n##\n(\"relationship\"<|>REFERENCES<|>AMERICAN THYROID ASSOCIATION<|>The references include studies and guidelines from the American Thyroid Association regarding thyroid disease management<|>3)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: del PTU parecen ser menos graves que los del tiamazol, por lo que se recomienda su utilización preferente, en caso de que sea necesario su uso, durante el primer trimestre de gestación.\n\nAsí, la Guía ATA 2017 indica que hasta la semana 16 de gestación se recomienda el PTU como tratamiento del hipertiroidismo materno, y que si estuvieran en tratamiento con tiamazol, deberían ser trasferidos a PTU tan pronto fuera posible. A partir de la semana 16 no hay evidencia ni a favor ni en contra de mantener el PTU o volver al tiamazol, por lo que no establecen ninguna recomendación al respecto (opción D falsa).\n\nReferencias:\n- Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27:315-89.\n- Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;24:1533-40.\n- Anderson SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab. 2016;101:1606-14.\n- Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab. 2000;85:3233-8.\n- Johansen K, Andersen AN, Kampmann JP, Mølholm Hansen JM, Mortensen HB. Excretion of methimazole in human milk. Eur J Clin Pharmacol. 1982;23:339-41.\n- Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86:2354-9.\n- Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, et al. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-403.\n\nCOMENTARIO\n\nLa amiodarona es un fármaco ampliamente utilizado en distintas patologías cardíacas, fundamentalmente como antiarrítmico, que posee la particularidad de ser extraordinariamente rico en yodo (37% de su peso), de forma que su utilización puede ocasionar trastornos en la función tiroidea que pueden manifestarse como hipotiroidismo o como diferentes formas de tirotoxicosis. Según las distintas series publicadas, la frecuencia global de hipotiroidismo oscila entre un 1% y un 32% de los pacientes tratados con amiodarona, y la de hipertiroidismo, entre un 1% y un 23% (opción A).\n\nUno de los mecanismos por el que la amiodarona afecta a la función tiroidea es por sus efectos citotóxicos directos sobre el tirocito. En efecto, en cultivos de folículos tiroideos humanos se ha comprobado la lisis del 50% de las células foliculares expuestas a amiodarona. Igualmente, se han descrito cambios ultraestructurales indicativos de toxicidad en cultivos de células tiroideas procedentes de distintas especies animales (opción B).\n\nLa disfunción tiroidea puede aparecer al inicio del tratamiento con amiodarona o aparecer años después de instaurado, incluso después de suspender el tratamiento. El motivo es que la amiodarona y sus metabolitos se almacenan en los tejidos, liberándose lentamente, de forma que sus efectos persisten incluso años después de la suspensión del tratamiento. Por lo tanto, la afirmación de la opción C es falsa.\n\nAdemás de los efectos anteriormente reseñados, la amiodarona puede inducir efectos similares al hipotiroidismo a nivel tisular, que puede estar relacionado con una reducción en el número de receptores catecolamínicos. No se conocen los mecanismos moleculares de estas acciones antagonistas de la amiodarona sobre los efectos de las hormonas tiroideas, pero podrían estar relacionados con una downregulation de los receptores a hormonas tiroideas causado por la amiodarona) (opción D).\n\nEn consecuencia, la respuesta correcta a esta pregunta es la C.\n\nReferencias:\n- Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134:2277-82.\n- Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.\n- Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F, et\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}